WO2008134923A1 - A preparation method of thiol derivative as side chain intermediate for synthesis of carbapenem derivative - Google Patents
A preparation method of thiol derivative as side chain intermediate for synthesis of carbapenem derivative Download PDFInfo
- Publication number
- WO2008134923A1 WO2008134923A1 PCT/CN2008/000814 CN2008000814W WO2008134923A1 WO 2008134923 A1 WO2008134923 A1 WO 2008134923A1 CN 2008000814 W CN2008000814 W CN 2008000814W WO 2008134923 A1 WO2008134923 A1 WO 2008134923A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- derivative
- branched
- chain intermediate
- iii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
Definitions
- the present invention relates to the field of organic chemistry and medicinal chemistry, and in particular, to a method for preparing a thiol derivative of a medicinal branched intermediate of piran. Background technique
- Peron (carbampenal) drugs such as imipenem, meropenem and biapenem have good antibacterial activity against many resistant bacteria, especially for B-type enzymes.
- (2S, 4S)-Substituted carbamoyl-4-mercapto- 1-(N-substituted) pyrrolizole (i) is an important branched intermediate of piranol drugs such as meropenem.
- a lower decyloxycarbonyl group, a halogenated decyloxycarbonyl group, a fluorenyloxycarbonyl group having a aromatic diameter, and a trimethylsilyl group, and R 4 and R 5 represent the same or different hospitals containing d-Cs carbon atoms.
- ⁇ can be tert-butoxycarbonyl, 2, 2, 2-trichloroethoxycarbonyl, 2-bromoethoxycarbonyl, o-nitrobenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, trimethyl A silyl group or a tert-butyldimethylsilyl group; and R 2 may be an ethoxycarbonyl group, a tert-butoxycarbonyl group, an isopropoxycarbonyl group, a methanesulfonyl group or a p-toluenesulfonyl group.
- R 4 and R 5 may be the same or different and include methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, propenyl, butenyl, phenyl, substituted phenyl, pyridyl, 2 Pyridinemethyl, 3-pyridylmethyl, 4-pyridylmethyl.
- the first method is to use t ns-4-hydroxy-L-proline as the raw material, protected by the amino group on the pyrrole ring, the 2-position carboxyl group is protected to form an ester, the 4-position hydroxyl group is substituted to obtain a vapor, and then the second position is hydrolyzed.
- the carboxylic acid, the amidation, and the 4-position hydrolysis are carried out in a total of 6 steps to obtain the compound (i), and the reaction route is as follows:
- Another method is to use trans- 4-hydroxy-L-proline as a raw material, protected by an amino group on a pyrrole ring, and the 2-position carboxyl group is directly reacted with a secondary amine to obtain an amide, and then substituted at the 4-position to obtain a compound (i). ), its synthetic route is as follows:
- Patent W09902513 mentions another route which uses amino-protected trans-4-hydroxy-L-proline as a raw material, is protected by a 2-carboxyl group, a 4-hydroxyl group, is ring-closed, and is ring-opened to obtain a compound (i).
- the synthetic route is as follows:
- the object of the present invention is to provide a preparation method of a perylene-based drug branched-chain intermediate-thiol derivative, and the synthetic route of the preparation method is as shown in formula 4:
- a method for preparing a peronal drug branched-chain intermediate monothiol alcohol derivative characterized in that the method comprises the following steps:
- the compound (vi) is hydrolyzed under basic conditions to obtain a thiol derivative (i) of a perindanic branched intermediate.
- a thiol derivative (i) of a perindanic branched intermediate represents an acyl compound.
- the compound (iii) and the compound (iv) are isolated, and the compound (v) is obtained in a one-pot method.
- the first two steps use a one-pot method to make the compound (iii) and the compound (iv) directly obtain the compound (v) without isolation, which simplifies the operation and reduces the production cost.
- the preparation method of the peronic drug branched-chain intermediate-monothiol derivative is characterized in that: from the compound (V) to the target (i), the compound (vi) is directly subjected to hydrolysis without drying treatment.
- the desired product thiol derivative (i) is obtained.
- the L-proline derivative (ii) is protected by a carboxyl group under the catalysis of an organic base to obtain a compound (iii) wherein the ratio of the organic base to the L-proline derivative (ii) is 1 to 4:1. Temperature is - 20 to 30 ° C;
- the compound (iii) is obtained by directly adding methylsulfonyl chloride for 0.4 to 3 hours without isolation to obtain a compound (iv) wherein the ratio of the methylsulfonyl chloride to the raw material L-proline derivative (ii) is 0.5 to 2 : 1, the reaction temperature is -35 ° C - 10 ° C;
- the compound (vi) is hydrolyzed in a basic alcohol solution to obtain the desired product thiol derivative (i), and the reaction temperature is -35 to 35° (the alkali solution concentration is 0.1 to 5 mol/L).
- the preparation method of the peronic drug branched-chain intermediate-monothiol derivative is characterized in that -
- the organic base used in the step A is triethylamine, diisopropylethylamine, pyridine, N,N-dimethylaniline, 4-(N,N-dimethylamino)pyridine, tri-n-propylamine or tri-n-butyl amine;
- the preparation method of the peronic drug branched-chain intermediate-monothiol derivative characterized in that - the aprotic solvent in step D is hydrazine, hydrazine-dimethylformamide, hydrazine, hydrazine-dimethyl methoxide Acetylamine, acetonitrile, dimethyl sulfoxide or pyridine.
- the alkaline solution in the crucible is sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium ethoxide, sodium methoxide in methanol or ethanol.
- the beneficial effects of the present invention are as follows: A method for preparing a peronic drug branched-chain intermediate-thiol derivative is provided, and the first two steps of the preparation method adopt a one-pot method to make the compound (iii) and the compound (iv) need not be used. Separation, direct compound (v), simplifies operation and reduces production costs. At the same time, by changing the process route, the product is easier to purify and the yield is improved. Compared with the prior patent literature, the invention has simple method, the intermediate does not need to be separated, the yield is high, the operation is easy, and the method is suitable for large-scale production. detailed description
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
Description
一种培南类药物支链中间体一一硫醇衍生物的制备方法 技术领域 Preparation method of perampanoid branched-chain intermediate-monothiol derivative
本发明涉及有机化学和药物化学领域, 具体而言, 本发明涉及一种培南 类药物支链中间体——硫醇衍生物的制备方法。 背景技术 The present invention relates to the field of organic chemistry and medicinal chemistry, and in particular, to a method for preparing a thiol derivative of a medicinal branched intermediate of piran. Background technique
培南(碳青霉烯)类药物如亚胺培南、 美罗培南和比亚培南对许多耐药 菌有良好的抗菌作用, 尤其是对 B型酶具有相当强的抑制作用, 是一系列独 特的抑制 内酰胺酶的抑制剂。 (2S, 4S) -取代氨基甲酰基 -4-巯基- 1- (N - 取代) 吡咯垸 (i ) 是培南类药物如美罗培南的重要支链中间体。 Peron (carbampenal) drugs such as imipenem, meropenem and biapenem have good antibacterial activity against many resistant bacteria, especially for B-type enzymes. A unique inhibitor of lactamase inhibition. (2S, 4S)-Substituted carbamoyl-4-mercapto- 1-(N-substituted) pyrrolizole (i) is an important branched intermediate of piranol drugs such as meropenem.
其中, 是低级垸氧基羰基、 卤代垸氧基羰基、 含芳香径的垸氧基羰基 和三垸基硅基, R4、 R5表示相同或不同的含 d-Cs个碳原子的院基、 含 C3-C4 个碳原子的烯烃基、 含 -(:3个碳的烃基取代的芳香基。 Among them, a lower decyloxycarbonyl group, a halogenated decyloxycarbonyl group, a fluorenyloxycarbonyl group having a aromatic diameter, and a trimethylsilyl group, and R 4 and R 5 represent the same or different hospitals containing d-Cs carbon atoms. a olefin group having a C 3 - C 4 carbon atom, a aryl group containing a - ( 3 hydrocarbon group substituted).
^可以是叔丁氧基羰基、 2, 2, 2-三氯乙氧基羰基, 2-溴乙氧基羰基、 邻 硝基苯甲氧基羰基、对硝基苯甲氧基羰基、三甲基硅基、叔丁基二甲基硅基; R2可以是乙氧基羰基、 叔丁氧基羰基、 异丙氧基羰基、 甲磺酰基、 对甲苯磺 酰基。 ^ can be tert-butoxycarbonyl, 2, 2, 2-trichloroethoxycarbonyl, 2-bromoethoxycarbonyl, o-nitrobenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, trimethyl A silyl group or a tert-butyldimethylsilyl group; and R 2 may be an ethoxycarbonyl group, a tert-butoxycarbonyl group, an isopropoxycarbonyl group, a methanesulfonyl group or a p-toluenesulfonyl group.
R4, R5可以相同或不同包括甲基、 乙基、 正丙基、 异丙基、 正丁基、 叔丁 基、 丙烯基、 丁烯基、 苯基、 取代苯基、 吡啶基、 2-吡啶甲基、 3-吡啶甲基、 4-吡啶甲基。 R 4 and R 5 may be the same or different and include methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, propenyl, butenyl, phenyl, substituted phenyl, pyridyl, 2 Pyridinemethyl, 3-pyridylmethyl, 4-pyridylmethyl.
sumitomo pharmaceuticals Co. , Ltd报道了两条化合物 (i ) 的合成路 线 [Makoto S觸 gawa, β -lactam compounds [P] , US4943569, 1990-7-24] 。 第一种方法是以 t ns-4-羟基- L-脯胺酸为原料,经吡咯环上的氨基保护, 2 位羧基保护成酯, 4位羟基取代得巯化物, 然后 2位再经水解得羧酸, 酰胺 化, 4位水解共 6步反应得化合物 (i ), 其反应路线如下式 1 : 另一种方法是以 trans- 4-羟基 -L-脯胺酸为原料, 经吡咯环上的氨基保 护, 2位羧基直接与仲胺反应得到酰胺,再通过 4位取代,水解得化合物(i ), 其合成路线如下式 2: Sumitomo pharmaceuticals Co., Ltd reported the synthetic route of two compounds (i) [Makoto S-touch gawa, β-lactam compounds [P], US 4943569, 1990-7-24]. The first method is to use t ns-4-hydroxy-L-proline as the raw material, protected by the amino group on the pyrrole ring, the 2-position carboxyl group is protected to form an ester, the 4-position hydroxyl group is substituted to obtain a vapor, and then the second position is hydrolyzed. The carboxylic acid, the amidation, and the 4-position hydrolysis are carried out in a total of 6 steps to obtain the compound (i), and the reaction route is as follows: Another method is to use trans- 4-hydroxy-L-proline as a raw material, protected by an amino group on a pyrrole ring, and the 2-position carboxyl group is directly reacted with a secondary amine to obtain an amide, and then substituted at the 4-position to obtain a compound (i). ), its synthetic route is as follows:
式 2 Equation 2
专利 W09902513 提到另为一条路线是以氨基已保护得 trans- 4-羟基 -L-脯胺 酸为原料, 经 2位羧基、 4位羟基保护, 关环, 开环得到化合物 (i ), 其合 成路线如下式 3: Patent W09902513 mentions another route which uses amino-protected trans-4-hydroxy-L-proline as a raw material, is protected by a 2-carboxyl group, a 4-hydroxyl group, is ring-closed, and is ring-opened to obtain a compound (i). The synthetic route is as follows:
式 3 发明内容 Formula 3 Summary of the Invention
本发明的目的在于提供一种培南类药物支链中间体一一硫醇衍生物的 制备方法, 该制备方法的合成路线如式 4: The object of the present invention is to provide a preparation method of a perylene-based drug branched-chain intermediate-thiol derivative, and the synthetic route of the preparation method is as shown in formula 4:
(v) (v)
(·) (·)
本发明方法的技术方案是: The technical solution of the method of the invention is:
^式 ^
一种培南类药物支链中间体一一硫 4醇衍生物的制备方法, 其特征在于该 方法包括下述步骤: A method for preparing a peronal drug branched-chain intermediate monothiol alcohol derivative, characterized in that the method comprises the following steps:
A)、 以 L-脯胺酸衍生物(ii)为原料,在有机碱存在下经羧基保护得到化 合物(iii): A), using L-proline derivative (ii) as a raw material, and protecting the compound (iii) by a carboxyl group in the presence of an organic base:
VN COORi VN COORi
B)、 化合物 (iii) 与甲基磺酰氯反应得到化合物 (iv): B), compound (iii) is reacted with methylsulfonyl chloride to give compound (iv):
0、 将化合物 (iv) 与盐酸二甲胺反应得到化合物 (V) 0. The compound (iv) is reacted with dimethylamine hydrochloride to obtain a compound (V)
D)、 将化合物 (v) 与硫代乙酸钾或硫代乙酸反应得到化合物 (vi) D), reacting compound (v) with potassium thioacetate or thioacetic acid to obtain compound (vi)
E)、 将化合物(vi)碱性条件下水解得到培南类药物支链中间体的硫醇 衍生物 (i)。 其中: 表示酰基化合物。 E), the compound (vi) is hydrolyzed under basic conditions to obtain a thiol derivative (i) of a perindanic branched intermediate. Wherein: represents an acyl compound.
所述的培南类药物支链中间体一一硫醇衍生物的制备方法, 其特征在 于: The preparation method of the peronic drug branched-chain intermediate-monothiol derivative is characterized in that:
从 L-脯胺酸衍生物(ii)到化合物(V), 化合物(iii)和化合物(iv) 是不经分离的, 直接一锅法得到化合物(v)。 前两步采用一锅法使得化合物 (iii), 化合物 (iv) 无需分离, 直接得到化合物 (v), 简化了操作, 降低 了生产成本。 From the L-proline derivative (ii) to the compound (V), the compound (iii) and the compound (iv) are isolated, and the compound (v) is obtained in a one-pot method. The first two steps use a one-pot method to make the compound (iii) and the compound (iv) directly obtain the compound (v) without isolation, which simplifies the operation and reduces the production cost.
所述的培南类药物支链中间体一一硫醇衍生物的制备方法, 其特征在 于: 从化合物 (V) 到目标物 (i), 其化合物 (vi) 不经干燥处理, 直接进 行水解得到目标产物硫醇衍生物 (i)。 The preparation method of the peronic drug branched-chain intermediate-monothiol derivative is characterized in that: from the compound (V) to the target (i), the compound (vi) is directly subjected to hydrolysis without drying treatment. The desired product thiol derivative (i) is obtained.
所述的培南类药物支链中间体一一硫醇衍生物的制备方法, 其特征在 于: The preparation method of the peronic drug branched-chain intermediate-monothiol derivative is characterized in that:
L -脯胺酸衍生物(ii)在有机碱的催化下经羧基保护得到化合物(iii), 其中有机碱与 L-脯胺酸衍生物 (ii) 的配比为 1〜4: 1, 反应温度为- 20〜 30°C; The L-proline derivative (ii) is protected by a carboxyl group under the catalysis of an organic base to obtain a compound (iii) wherein the ratio of the organic base to the L-proline derivative (ii) is 1 to 4:1. Temperature is - 20 to 30 ° C;
得到化合物(iii) 不经分离, 直接加入甲基磺酰氯反应 0.4〜3小时得 到化合物(iv),其中甲基磺酰氯与原料 L-脯胺酸衍生物(ii)的配比为 0.5〜 2: 1, 反应温度为 -35°C- 10°C; The compound (iii) is obtained by directly adding methylsulfonyl chloride for 0.4 to 3 hours without isolation to obtain a compound (iv) wherein the ratio of the methylsulfonyl chloride to the raw material L-proline derivative (ii) is 0.5 to 2 : 1, the reaction temperature is -35 ° C - 10 ° C;
化合物 (iv) 加盐酸二甲胺反应 0.5〜6小时得到化合物 (V), 其中盐 酸二甲胺与原料 L-脯胺酸衍生物(ii)的配比为 0.5〜2: 1, 反应温度在- 35 °C- 10°C; Compound (iv) is reacted with dimethylamine hydrochloride for 0.5 to 6 hours to obtain compound (V), wherein the ratio of dimethylamine hydrochloride to the starting material L-proline derivative (ii) is 0.5 to 2: 1, and the reaction temperature is - 35 °C - 10 °C;
化合物 (V) 与硫代乙酸钾或硫代乙酸在非质子性溶剂中, 25〜60°C反 应 10〜25小时得到化合物(vi); 其中硫代乙酸钾或硫代乙酸与化合物(V) 的配比为 0.5〜3: 1 Compound (V) is reacted with potassium thioacetate or thioacetic acid in an aprotic solvent at 25 to 60 ° C for 10 to 25 hours to obtain compound (vi); wherein potassium thioacetate or thioacetic acid and compound (V) The ratio is 0.5~3: 1
化合物(vi)在碱性醇溶液中水解反应,得到目标产物硫醇衍生物(i), 反应温度- 35〜35° ( , 碱溶液浓度 0. l〜5mol/L。 The compound (vi) is hydrolyzed in a basic alcohol solution to obtain the desired product thiol derivative (i), and the reaction temperature is -35 to 35° (the alkali solution concentration is 0.1 to 5 mol/L).
所述的培南类药物支链中间体一一硫醇衍生物的制备方法, 其特征在 于- 步骤 A中用的有机碱是三乙胺, 二异丙基乙胺, 吡啶, N, N-二甲基苯 胺, 4_ (N, N-二甲基氨基) 吡啶, 三正丙胺或三正丁胺; The preparation method of the peronic drug branched-chain intermediate-monothiol derivative is characterized in that - The organic base used in the step A is triethylamine, diisopropylethylamine, pyridine, N,N-dimethylaniline, 4-(N,N-dimethylamino)pyridine, tri-n-propylamine or tri-n-butyl amine;
所述的培南类药物支链中间体一一硫醇衍生物的制备方法, 其特征在 于- 步骤 D中的非质子性溶剂是 Ν, Ν-二甲基甲酰胺、 Ν,Ν-二甲基乙酰胺、 乙 腈、 二甲亚砜或吡啶。 The preparation method of the peronic drug branched-chain intermediate-monothiol derivative, characterized in that - the aprotic solvent in step D is hydrazine, hydrazine-dimethylformamide, hydrazine, hydrazine-dimethyl methoxide Acetylamine, acetonitrile, dimethyl sulfoxide or pyridine.
所述的培南类药物支链中间体一一硫醇衍生物的制备方法, 其特征在 于: The preparation method of the peronic drug branched-chain intermediate-monothiol derivative is characterized in that:
步骤 Ε中的碱性溶液是氢氧化钠、氢氧化钾、碳酸钠、碳酸钾、 乙醇钠、 甲醇钠的甲醇溶液或乙醇溶液。 本发明的有益效果是; 提供了一种培南类药物支链中间体一一硫醇衍生 物的制备方法, 该制备方法前两步采用一锅煮的方法使得化合物(iii )、 化 合物(iv)无需分离, 直接得到化合物(v), 简化了操作, 降低了生产成本。 同时, 通过改变工艺路线, 产品更易提纯, 提高了收率。 本发明较已有专利 文献报导的方法简单, 中间体不需分离, 收率高, 易于操作, 适合大规模生 产。 具体实施方式 Step The alkaline solution in the crucible is sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium ethoxide, sodium methoxide in methanol or ethanol. The beneficial effects of the present invention are as follows: A method for preparing a peronic drug branched-chain intermediate-thiol derivative is provided, and the first two steps of the preparation method adopt a one-pot method to make the compound (iii) and the compound (iv) need not be used. Separation, direct compound (v), simplifies operation and reduces production costs. At the same time, by changing the process route, the product is easier to purify and the yield is improved. Compared with the prior patent literature, the invention has simple method, the intermediate does not need to be separated, the yield is high, the operation is easy, and the method is suitable for large-scale production. detailed description
. 下面通过具体实施例来进一步说明本发明。 The invention is further illustrated by the following examples.
实施例 1 (2S, 4R) 1- (对硝基苄氧基羰基) -2- (N, N-二甲基氨基 酰基) -4-甲磺酸基吡咯垸的制备 Example 1 Preparation of (2S, 4R) 1-(p-nitrobenzyloxycarbonyl)-2-(N,N-dimethylaminoacyl)-4-methanesulfonylpyrrole
在 500ml反应瓶中加入二氯甲烷(300ml ), 搅拌, 加入 N-对硝基苄氧基 羰基- 4- S-羟基脯氨酸(20g, 64. 5mmol ),冷却至 - 20°C,加入三乙胺(19. 5g, 193mmol ), 搅拌 5分钟, 滴加氯甲酸异丙酯 (8. 2g, 67. 2mmol ), 约滴加 1 小时, 反应 5小时后, 继续降温至 -35°C, 然后分批加入甲磺酰氯 (14. 7g, 128mmol ),加完后继续搅拌 3小时,然后加入盐酸二甲胺(5. 3g, 64. 5mmol ), 搅拌反应 6小时后加入水 120ml, 萃取分层, 有机层用无水硫酸钠干燥, 减 压下蒸除溶剂, 然后加入乙酸乙酯溶解, 滴加石油醚析出固体, 过滤, 烘千 得中间体 (2S, 4R) 1- (对硝基苄氧基羰基) -2- (N, N-二甲基氨基酰基) - 4 -甲磺酸基吡咯垸 (21. lg, 78. 7% )。 Add dichloromethane (300 ml) to a 500 ml reaction flask, stir, add N-p-nitrobenzyloxycarbonyl-4-S-hydroxyproline (20 g, 64.5 mmol), cool to -20 ° C, add Triethylamine (19.5 g, 193 mmol), stirred for 5 minutes, isopropyl chloroformate (8.2 g, 67. 2 mmol) was added dropwise, about 1 hour dropwise, and after 5 hours of reaction, the temperature was further lowered to -35 ° C. Then, methanesulfonyl chloride (14.7 g, 128 mmol) was added in portions, and stirring was continued for 3 hours, then dimethylamine hydrochloride (5.3 g, 64. 5 mmol) was added, and the reaction was stirred for 6 hours, then 120 ml of water was added, and extracted. The organic layer was dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure, then ethyl acetate was dissolved, and the solid was precipitated with petroleum ether, filtered, and dried to obtain intermediate (2S, 4R) 1- (Benzyloxycarbonyl)-2-(N,N-dimethylaminoacyl)-4-carboxysulfonylpyrrole (21. lg, 78.7%).
实施例 2 (2S, 4S) 1- (对硝基苄氧基羰基) -2- (N, N-二甲基氨基 酰基) -4 -巯基吡咯烷的制备 Example 2 (2S, 4S) 1-(p-Nitrobenzyloxycarbonyl)-2-(N,N-dimethylamino Preparation of acyl)-1,4-mercaptopyrrolidine
在 250ml反应瓶中加入 DMF ( 150ml ),(2S, 4R) 1_对硝基苄氧基羰基- 2- (N, N-二甲基氨基酰基) - 4-S -甲磺酸基吡咯垸 (15. 0g, 36iranol ), 搅拌 溶解, 加入硫代乙酸钾 (4. 3g, 37. 7mmol) , 25°C下反应 10小时, 然后快速 倒入 1000ml冰水中, 搅拌析出固体, 过滤得湿品。 In a 250 ml reaction flask was added DMF (150 ml), (2S, 4R) 1_p-nitrobenzyloxycarbonyl-2-(N,N-dimethylaminoacyl)-4-S-methanesulfonate (15. 0g, 36iranol), stirred and dissolved, added potassium thioacetate (4.3 g, 37.7 mmol), reacted at 25 ° C for 10 hours, then quickly poured into 1000 ml of ice water, stirred to precipitate a solid, filtered to obtain a wet product .
将得到的湿品加入 100ml二氯甲烷中, 搅拌, 然后加入 0. lmol/L氢氧 化钠甲醇溶液 15ml, 5 °C下搅拌反应 5分钟,然后加入稀盐酸调 PH值至 2. 5〜3 左右, 分层, 有机层减压下蒸干, 加入甲醇溶解, 然后加入石油醚析出固体, 过滤, 烘干得 (2S, 4S) 1- (对硝基苄氧基羰基) -2- (N, N-二甲基氨基酰 基) -4 -巯基吡咯垸 ( 12. 2g, 95%)。 0〜3〜3〜3〜3〜3〜3〜3〜3〜3〜3〜3〜3〜3〜3〜3〜3〜3〜3〜3~3~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ Left and right, layered, the organic layer was evaporated to dryness under reduced pressure, dissolved in methanol, and then solidified with petroleum ether, filtered and dried to give (2S, 4S) 1- (p-nitrobenzyloxycarbonyl) -2- (N , N-Dimethylaminoacyl)-4-indolylpyrrole (12. 2g, 95%).
实施例 3 (2S, 4R) 1- (对硝基苄氧基羰基) -2- (N, N-二甲氨基酰基) -4-甲磺酸基吡咯垸的制备 Example 3 Preparation of (2S, 4R) 1-(p-nitrobenzyloxycarbonyl)-2-(N,N-dimethylaminoyl)-4-methanesulfonylpyrrole
在烧瓶中加入二氯甲烷(250ml ),搅拌,加入 N-对硝基苄氧基羰基- 4 - S- 羟基脯氨酸 (16. 2g, 52匪 ol ), 冷却至 5°C, 加入二异丙基乙胺 (6. 4g, 55函 ol ), 搅拌 5〜10分钟, 滴加氯甲酸乙酯 5. 7g, 52. 8画1 ), 约滴加 1 小时, 反应 2小时后滴加甲磺酰氯 (6g, 52. 2mmol ), 加完后继续搅拌 1小 时,然后加入盐酸二甲胺(8. 2g, lOOmmol ),搅拌反应 2小时后加入水 100ml, 萃取分层, 有机层用无水硫酸钠干燥, 减压下蒸除溶剂, 然后加入乙醇搅拌 溶解, 滴加石油醚析出固体, 过滤, 烘干得中间体 ((2S, 4R) 1 (对硝基 苄氧基羰基) -2- (N, N-二甲氨基酰基) -4-甲磺酸基吡咯垸(17. 8g, 82%)。 Add dichloromethane (250 ml) to the flask, stir, add N-p-nitrobenzyloxycarbonyl-4-S-hydroxyproline (16.2 g, 52 匪ol), cool to 5 ° C, add two Isopropylethylamine (6.4 g, 55 ol), stirring for 5 to 10 minutes, dropwise addition of ethyl chloroformate 5. 7 g, 52. 8 paintings 1 ), about 1 hour dropwise, 2 hours after the reaction, adding dropwise Methanesulfonyl chloride (6 g, 52.2 mmol), stirring was continued for 1 hour after the addition, then dimethylamine hydrochloride (8.2 g, 100 mmol) was added, and the reaction was stirred for 2 hours, then 100 ml of water was added, and the layers were separated, and the organic layer was used. Drying with sodium sulfate, distilling off the solvent under reduced pressure, then adding ethanol, stirring and dissolving, adding petroleum ether to precipitate a solid, filtering, and drying to obtain intermediate ((2S, 4R) 1 (p-nitrobenzyloxycarbonyl) -2 - (N, N-Dimethylaminoacyl)-4-methylsulfonylpyrrole (17. 8 g, 82%).
实施例 4 (2S, 4S) 1- (对硝基苄氧基羰基) -2- (N, N-二甲氨基酰 基) -4-巯基吡咯烷的制备 Example 4 Preparation of (2S, 4S) 1-(p-nitrobenzyloxycarbonyl)-2-(N,N-dimethylaminoyl)-4-indolylpyrrolidine
在 250ml反应瓶中加入 DMF ( 120ml ), (2S, 4R) 1 -对硝基苄氧基羰基- (2-N, N-二甲氨基酰基) -4-甲磺酸基吡咯垸(13. 3g, 31. 9mmol ), 搅拌溶 解, 加入硫代乙酸 (4. 85g, 63. 8mmol ), 60°C下反应 25小时, 然后快速倒 入 1000ml冰水中, 搅拌析出固体, 过滤得湿品。 In a 250 ml reaction flask was added DMF (120 ml), (2S, 4R) 1-p-nitrobenzyloxycarbonyl-(2-N,N-dimethylaminoacyl)-4-methanesulfonylpyrrole (13. 3 g, 31. 9 mmol), stirred and dissolved, added thioacetic acid (4.85 g, 63.8 mmol), and reacted at 60 ° C for 25 hours, then quickly poured into 1000 ml of ice water, and the precipitated solid was stirred and filtered to obtain a wet product.
将得到的湿品加入 100ml二氯甲垸中, 搅拌, 然后加入 5mol/L氢氧化 钾乙醇溶液 30ml, 一 25°C下搅拌反应一小时, 然后加入稀盐酸调 PH值至 2. 5〜3左右, 分层, 有机层减压下蒸千, 加入甲醇溶解, 然后加入石油醚析 出固体, 过滤, 烘干得 (2S, 4S) 1- (对硝基苄氧基羰基) -2- (N, N-二甲 氨基酰基) -4-巯基吡咯垸 (9. 6g, 85%)。 0〜3〜3〜3〜3~3~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ Left and right, layered, the organic layer is steamed under reduced pressure, dissolved in methanol, and then added with petroleum ether to precipitate a solid, which is filtered and dried to give (2S, 4S) 1-(p-nitrobenzyloxycarbonyl)-2-(N , N-dimethylamino acyl)-4-mercaptopyrrole (9. 6g, 85%).
实施例 5 (2S, 4R) 1- (对硝基苄氧基羰基) -2- (N, N-二甲氨基酰 基) -4-甲磺酸基吡咯垸的制备 Example 5 (2S, 4R) 1-(p-Nitrobenzyloxycarbonyl)-2-(N,N-dimethylamino) Preparation of -4-methylsulfonylpyrrole
在 500ml反应瓶中加入二氯甲烷(300ml), 搅拌, 加入 N-对硝基苄氧基 羰基- 4-S-羟基脯氨酸(20g, 64.5腿 ol), 30°C加入吡啶(20.3g, 257mmol), 搅拌^ 10钟, 滴加氯甲酸叔丁酯(9.2g, 67.6mmol), 0.5〜1小时滴加完毕, 保持 30°C下反应 1小时后, 将温度降至 10°C, 然后滴加甲磺酰氯 (4. lg, 35.5mmol), 加完后继续搅拌 0.4 小时, 然后加入盐酸二甲胺 (2.7g, 33. lmmol), 搅泮反应 0.5小时后加入水 120ml, 萃取分层, 有机层用无水硫 酸钠干燥,减压下蒸除溶剂,然后加入乙酸乙酯溶解,滴加石油醚析出固体, 过滤, 烘干得中间体 (2S, 4R) 1- (对硝基苄氧基羰基) -2- (N, N-二甲氨 基酰基) - 4-甲磺酸基吡咯烷 (15.0g, 56%)。 Dichloromethane (300 ml) was added to a 500 ml reaction flask, stirred, and N-p-nitrobenzyloxycarbonyl-4-S-hydroxyproline (20 g, 64.5 leg ol) was added, and pyridine (20.3 g) was added at 30 °C. , 257 mmol), stirred for 10 minutes, t-butyl chloroformate (9.2 g, 67.6 mmol) was added dropwise, and the addition was completed in 0.5 to 1 hour. After maintaining the reaction at 30 ° C for 1 hour, the temperature was lowered to 10 ° C. Then, methanesulfonyl chloride (4. lg, 35.5 mmol) was added dropwise. After the addition was completed, stirring was continued for 0.4 hours, then dimethylamine hydrochloride (2.7 g, 33. lmmol) was added, and the reaction was stirred for 0.5 hour, then 120 ml of water was added, and the extract was extracted. The organic layer is dried over anhydrous sodium sulfate, and the solvent is evaporated under reduced pressure, then ethyl acetate is dissolved, and the solid is precipitated with petroleum ether, filtered, and dried to give intermediate (2S, 4R) 1- Benzyloxycarbonyl)-2-(N,N-dimethylaminoacyl)-4-methanesulfonylpyrrolidine (15.0 g, 56%).
实施例 6 (2S, 4S) 1- (对硝基苄氧基羰基) -2- (N, N-二甲氨基酰 基) -4-巯基吡咯垸的制备 Example 6 Preparation of (2S, 4S) 1-(p-nitrobenzyloxycarbonyl)-2-(N,N-dimethylaminoyl)-4-mercaptopyrrole
在反应瓶中加入 DMSO (75ml), (2S, 4R) 1_ (对硝基苄氧基羰基) - 2- (N, N-二甲氨基酰基) -4-甲磺酸基吡咯垸(8. lg, 19.5mmol), 搅拌溶解, 加入硫代乙酸钾(6.8g, 58.7ranol), 40°C下反应 21小时,然后快速倒入 600ml 冰水中, 搅拌析出固体, 过滤得湿品。 In the reaction flask was added DMSO (75 ml), (2S, 4R) 1_(p-nitrobenzyloxycarbonyl)-2-(N,N-dimethylaminoacyl)-4-methanesulfonylpyrrole (8. Lg, 19.5 mmol), stirred and dissolved, added potassium thioacetate (6.8 g, 58.7 ranol), and reacted at 40 ° C for 21 hours, then quickly poured into 600 ml of ice water, stirred to precipitate a solid, and filtered to obtain a wet product.
将得到的湿品加入 80ml二氯甲垸中, 搅拌, 然后加入 2mol/L乙醇钠的 乙醇溶液 30ml, 35°C下搅拌反应 50分钟, 然后加入稀盐酸调 PH值至 2.5~3 左右, 分层, 有机层减压下蒸干, 加入甲醇溶解, 然后加入石油醚析出固体, 过滤, 烘干得(2S, 4S) 1- (对硝基苄氧基羰基) -2- (N, N-二甲氨基酰基) -4-巯基吡咯垸 (3.9g, 56.6%)。 Add the obtained wet product to 80 ml of dichloromethane, stir, then add 30 ml of 2 mol/L sodium ethoxide in ethanol, stir the reaction at 35 ° C for 50 minutes, then add dilute hydrochloric acid to adjust the pH to 2.5~3, The organic layer is evaporated to dryness under reduced pressure, dissolved in methanol, and then petroleum ether is added to precipitate a solid, which is filtered and dried to give (2S, 4S) 1-(p-nitrobenzyloxycarbonyl)-2-(N, N- Dimethylamino)-4-indolylpyrrole (3.9 g, 56.6%).
实施例 7 (2S, 4R) 1- (对硝基苄氧基羰基) -2- (N, N-二甲氨基酰 基) -4-甲磺酸基吡咯垸的制备 Example 7 Preparation of (2S, 4R) 1-(p-nitrobenzyloxycarbonyl)-2-(N,N-dimethylaminoyl)-4-methylsulfonylpyrrole
在 500ml反应瓶中加入二氯甲垸(300ml), 搅拌, 加入 N-对硝基苄氧基 羰基 -4- S-羟基脯氨酸 (20g, 64.5mmol), _5°C加入二异丙基乙胺 (14.9g, 129讓 ol), 搅拌 5〜: L0钟, 滴加氯甲酸乙酯 (7. lg, 65.5画1), 0.5〜1小时 滴加完毕, 反应 3小时后滴加甲磺酰氯 (9.9, 86.8mmol), 加完后继续搅拌 1.5〜2小时, 然后加入盐酸二甲胺(5.4g, 66mmol), 搅拌反应 4小时后加入 水 120ml, 萃取分层, 有机层用无水硫酸钠干燥, 减压下蒸除溶剂, 然后加 入乙酸乙酯溶解, 滴加石油醚析出固体, 过滤, 烘干得中间体 (2S, 4R) 1 - (对硝基苄氧基羰基)-2- (N, N-二甲氨基酰基)-4-甲磺酸基吡咯垸(22.5g, 实施例 8 (2S, 4S) 1- (对硝基苄氧基羰基) -2- (N, N-二甲氨基酰 基) -4-巯基吡咯烷的制备 Add methylene chloride (300 ml) to a 500 ml reaction flask, stir, add N-p-nitrobenzyloxycarbonyl-4-S-hydroxyproline (20 g, 64.5 mmol), add isopropyl at _5 °C Ethylamine (14.9g, 129 let ol), stir 5~: L0 clock, add ethyl chloroformate (7. lg, 65.5 draw 1), add 0.5~1 hour, add methyl sulfonate after 3 hours of reaction Acid chloride (9.9, 86.8 mmol), stirring was continued for 1.5 to 2 hours after the addition, then dimethylamine hydrochloride (5.4 g, 66 mmol) was added, and the reaction was stirred for 4 hours, then 120 ml of water was added, and the layers were separated, and the organic layer was treated with anhydrous sulfuric acid. Dry the sodium, distill the solvent under reduced pressure, then dissolve with ethyl acetate, add petroleum ether to precipitate a solid, filter, and dry to give intermediate (2S, 4R) 1 - (p-nitrobenzyloxycarbonyl)-2- (N, N-dimethylamino)-4-methanesulfonate pyrrolidine (22.5 g, Example 8 Preparation of (2S, 4S) 1-(p-Nitrobenzyloxycarbonyl)-2-(N,N-dimethylaminoyl)-4-indolylpyrrolidine
在反应瓶中加入乙腈( 100ml ), (2S, 4R) 1- (对硝基苄氧基羰基) - 2 - (N, N-二甲氨基酰基) -4-甲磺酸基吡咯垸(15g, 36mmol ), 搅拌溶解, 加 入硫代乙酸钾(2. lg, 18. 4mmol ), 35°C下反应 14小时,然后快速倒入 800ml 冰水中, 搅拌析出固体, 过滤得湿品。 In the reaction flask was added acetonitrile (100 ml), (2S, 4R) 1-(p-nitrobenzyloxycarbonyl)-2-(N,N-dimethylaminoacyl)-4-methanesulfonylpyrrole (15 g) , 36 mmol), stirred and dissolved, added potassium thioacetate (2. lg, 18. 4 mmol), and reacted at 35 ° C for 14 hours, then quickly poured into 800 ml of ice water, and the precipitated solid was stirred and filtered to obtain a wet product.
将得到的湿品加入 100ml二氯甲垸中, 搅拌, 然后加入 0. 2mol/L碳酸 钠乙醇溶液 20ml, -35 "C下搅拌反应 20分钟,然后加入稀盐酸调 PH值至 2. 5〜3 左右, 分层, 有机层减压下蒸干, 加入甲醇溶解, 然后加入石油醚析出固体, 过滤, 烘干得(2S, 4S) 1- (对硝基苄氧基羰基) -2- (N, N-二甲氨基酰基) -4-巯基吡咯垸 (9. 3g, 73%)。 5〜 The pH is adjusted to 2. 5~ Add the diluted hydrochloric acid to adjust the pH value to 2. 5~ 3, layering, the organic layer is evaporated to dryness under reduced pressure, dissolved in methanol, then added to petroleum ether to precipitate solids, filtered, and dried to give (2S, 4S) 1-(p-nitrobenzyloxycarbonyl)-2- ( N, N-dimethylamino acyl)-4-mercaptopyrrole (9.3 g, 73%).
Claims
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200710068259.X | 2007-04-28 | ||
| CNA200710068259XA CN101041632A (en) | 2007-04-28 | 2007-04-28 | Preparation method of penem drug branched chain intermediate-mercaptan derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2008134923A1 true WO2008134923A1 (en) | 2008-11-13 |
Family
ID=38807449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2008/000814 Ceased WO2008134923A1 (en) | 2007-04-28 | 2008-04-21 | A preparation method of thiol derivative as side chain intermediate for synthesis of carbapenem derivative |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN101041632A (en) |
| WO (1) | WO2008134923A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012079289A1 (en) * | 2010-12-16 | 2012-06-21 | 珠海亿邦制药股份有限公司 | Amorphous powder and polymorph of carbapenem derivative, preparation method therefor and use thereof |
| CN105439932B (en) * | 2014-08-27 | 2018-06-29 | 北大方正集团有限公司 | A kind of penem-like pharmaceutical intermediate and preparation method thereof |
| CN105439933B (en) * | 2014-08-27 | 2017-11-24 | 北大方正集团有限公司 | A kind of preparation method of penem-like pharmaceutical mercaptan side chain |
| CN114163371B (en) * | 2021-12-21 | 2024-05-14 | 天津市敬业精细化工有限公司 | Meropenem side chain optical isomer, preparation method and application thereof, and meropenem side chain impurity detection method |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4943569A (en) * | 1983-05-09 | 1990-07-24 | Sumitomo Pharmaceuticals Co., Ltd. | B-lactam compounds |
| WO1999002513A1 (en) * | 1997-07-09 | 1999-01-21 | Novo Nordisk A/S | Preparation of diaryl-benzopyrans |
-
2007
- 2007-04-28 CN CNA200710068259XA patent/CN101041632A/en active Pending
-
2008
- 2008-04-21 WO PCT/CN2008/000814 patent/WO2008134923A1/en not_active Ceased
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4943569A (en) * | 1983-05-09 | 1990-07-24 | Sumitomo Pharmaceuticals Co., Ltd. | B-lactam compounds |
| WO1999002513A1 (en) * | 1997-07-09 | 1999-01-21 | Novo Nordisk A/S | Preparation of diaryl-benzopyrans |
Non-Patent Citations (1)
| Title |
|---|
| MAKOTO S. ET AL.: "A novel carbapenem antibiotic, SM-7338 structure-activity relationships", THE JOURNAL OF ANTIBIOTICS, vol. 43, no. 5, pages 519 - 532, XP002912928 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101041632A (en) | 2007-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0570594B1 (en) | Hydroxamic acid derivative based on aromatic sulfonamide | |
| US8981105B2 (en) | Process of preparing a thrombin specific inhibitor | |
| CN103649055B (en) | For the preparation of the method for pyrazole derivatives | |
| CZ293694B6 (en) | Pharmaceutical composition containing 4-mercaptopyrrolidine derivatives as farnesyl transferase inhibitors | |
| WO2006019020A1 (en) | Substituted ureas | |
| TWI426074B (en) | Method for producing 5-(2-amino-pyrimidin-4-yl)-2-aryl-1H-pyrrole-3-carboxamide | |
| WO2009129370A1 (en) | Cathepsin c inhibitors | |
| WO2001000587A1 (en) | Azolylbenzamides and analogues and their use for treating osteoporosis | |
| WO2016181414A1 (en) | Process for the synthesis of ivacaftor and related compounds | |
| CN110041333A (en) | Bromine structural domain inhibitor compound and application thereof | |
| WO2010121382A1 (en) | Process for making indole cyclopropyl amide derivatives | |
| WO2016017711A1 (en) | Pyrazole derivative manufacturing method | |
| WO2004108673A2 (en) | Inhibitors of papilloma virus | |
| WO2008134923A1 (en) | A preparation method of thiol derivative as side chain intermediate for synthesis of carbapenem derivative | |
| WO2000027792A1 (en) | Novel compounds and medicinal use thereof | |
| CN104860935A (en) | Thiophene or its variant derivatives as hepatitis C virus inhibitor and pharmaceutical use thereof | |
| KR20250007528A (en) | 5-Pyridine-1H-indazole compounds, pharmaceutical compositions and applications | |
| TWI887245B (en) | Processes and intermediates for producing diazaspiro lactam compounds | |
| KR20010033528A (en) | Indole Derivatives Useful A.O. for the Treatment of Osteoporosis | |
| WO2011095125A1 (en) | Synthesis methods and purification methods of dasatinib | |
| CN102199132A (en) | Method for preparing 2-(2-amino-4-thiazole)-2(Z)-[[(tertbutyloxycarbonyl) methoxyl] imido] acetic acid and salt thereof | |
| JP2001519328A (en) | Azetidinone derivatives for the treatment of HCMV infection | |
| WO2007009354A1 (en) | Pyrrolidine derivative intermediates,preparation and usage thereof | |
| CN100422170C (en) | The preparation method of quinolone carboxylic acid derivative | |
| CN117164582A (en) | A kind of protease inhibitor and pharmaceutical composition and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08734005 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 08734005 Country of ref document: EP Kind code of ref document: A1 |